Medimmune Limited

Spirogen Limited

Seattle Genetics, Inc.

Adc Therapeutics Sa

Spirogen Sarl

Genentech, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Midwest Research Institute

Abbvie Stemcentrx LLC

Starks Associates Inc.

Other

Medimmue Limited

Spirogen Developments Sarl

Adc Therpeutics S.a.

Seagen Inc.

Philip Wilson Howard

Patricius Hendrikus Cornelis Van Berkel

David Edwin Thurston

Luke Masterson

Stephen John Gregson

Scott C Jeffrey

Patrick J Burke

Arnaud Charles Tiberghien

John A Flygare

Thomas Pillow

Peter Senter

Binqing Wei

Zhizhi Chen

Thais Cailleau

Paul S Liu

B Rao Vishnuvajjala

Janet L Gunzner-Toste

Kenneth M Snader

Brian Salvatore Safina

Michael Torgov

Guiling Zhao

Vishal Verma

Leanna Staben

Luke Y Hsiao

Gregory Turner

Niall Dickinson

Peter William Taylor

Paul Polakis

Andrew G Polson

Susan D Spencer

Khondaker Mirazur Rahman

Patricius Henrikus Cornelis Van Berkel

Nazzareno Dimasi

David Gareth Williams

Geoffrey Wells

John Hartley

Helga E Raab

Gary Kemp

Patricius Hendrikus Van Berkel

Arnaud Tiberghien

Jason White

Balakumar Vijayakrishnan

Elizabeth Dunny

William Goundry

Jean-Noel Levy

Tsveta Stefanova Hadjivassileva

Gyoung-Dong Kang

Thaïs Cailleau

Ebele Ezeadi

Francois D'Hooge

Neki Patel

B Rao Vishnuvaijala

Tsveta Stepanova Hadjivassileva

Peter William School Of Pharmacy Taylor

Janet Gunzner-Toste

Janet L Gunzner

Francois D'hooge

A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.

Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer

A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Pyrrolobenzodiazepines and conjugates thereof

Conjugates of an antibody that binds to CD25 with PBD dimers.

Pyrrolobenzodiazepine-antibody conjugates

Conjugates of an antibody that binds to CD19 with PBD dimers.

A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

Site-specific antibody-drug conjugates

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.

Peptidomimetic compounds and antibody-drug conjugates thereof

The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

A conjugate of formula (I) wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain. 

Pyrrolobenzodiazepine conjugates

A compound with the formula I: (I) and salts and solvates thereof, wherein: R&#x2033; is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3. 

Pyrrolobenzodiazepines and conjugates thereof as antitumour agents

A conjugate of formula I:L-(D)&#x2003;&#x2003;(1) wherein L is a Ligand unit, Dis a Drug Linker unit of formula II:  wherein either: (a) Rand Rform a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (b) Ris OH, and Ris:  p is an integer of from 1 to 20.

Pyrrolobenzodiazepine antibody conjugates

A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Compounds and conjugates thereof

A compound of formula I and salts and solvates thereof, wherein: Rand Rare independently selected from H, R, OH, OR, SH, SR, NH, NHR, NRR', nitro, MeSn and halo; where R and R&#x2032; are independently selected from optionally substituted Calkyl, Cheterocyclyl and Caryl groups; Ris selected from H, R, OH, OR, SH, SR, NH, NHR, NRR&#x2032;, nitro, MeSn and halo; R&#x2033; is a Calkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NR(where Ris H or Calkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y&#x2032; are selected from O, S, or NH; R, R, Rare selected from the same groups as R, Rand Rrespectively; Ris selected from OH, OR, where Ris Calkyl; and Ris a linker for connection to a cell binding agent. 

A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety;

Growing community of inventors

London, United Kingdom

Philip Wilson Howard